Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. - Wikidata - wikimedia - TriplyDB

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.

http://www.wikidata.org/entity/Q34038480

about

VEGF-Trap: a VEGF blocker with potent antitumor effects.From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway Targeting angiogenesis in gynecologic cancers Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3 The antiangiogenic effects of a vascular endothelial growth factor decoy receptor can be monitored in vivo using contrast-enhanced ultrasound imaging.Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy.Tumour vascularization: sprouting angiogenesis and beyond Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer.Vascular endothelial growth factor and its receptors in multiple myeloma.Exploiting novel molecular targets in gastrointestinal cancers.Aflibercept in the treatment of metastatic colorectal cancer.Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma Combination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer model DCE and DW-MRI monitoring of vascular disruption following VEGF-Trap treatment of a rat glioma model Recent developments in antiangiogenic therapy.Development of novel DNA vaccine for VEGF in murine cancer model VEGF blocking therapy in the treatment of cancer.Regression of established tumors and metastases by potent vascular endothelial growth factor blockade.Targeting the tumor microenvironment: focus on angiogenesis.Targeting angiogenesis for controlling neuroblastoma.Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3.Nucleic acid aptamers as tools and drugs: recent developments.Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiforme Fibroblast stimulation of blood vessel development and cancer cell invasion in a subrenal capsule xenograft model: stress-induced premature senescence does not increase effect.Monoclonal antibodies for brain tumour treatment.Anti-VEGF/VEGFR therapy for cancer: reassessing the target.The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity.Monitoring early tumor response to drug therapy with diffuse optical tomography.mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling.Emerging treatment options for management of malignant ascites in patients with ovarian cancer.Delivery of antiangiogenic agents for cancer gene therapy.A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors.A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report Neuropilin 1 Involvement in Choroidal and Retinal Neovascularisation.

P2860

Q24535043-58B74C71-3C93-49E2-AD10-1766C6DDBB77 Q24621007-0871F964-3E8F-43C0-8A37-286B84C3E51E Q26824766-7AA981AF-8271-4CAA-BE10-69FACEC0C38C Q28077123-55C4A001-16F7-4C83-A826-1019A41DF57F Q28564217-BF4E1813-CB9B-4A4C-97AF-0E372D7CFE0D Q30409780-E964D372-1FC6-4B5B-B5DE-9CC2F78144F8 Q30424925-103E3FBF-542C-4F28-B63B-82A22DFFC46A Q30454165-15D4DA67-53E8-45A3-99E1-B33A51853B00 Q33556162-D680279B-BB94-4EE0-B0F5-5E5C6C167C50 Q34000985-7FA8CE69-4890-4837-BC0E-C407ABAE4D6A Q34265556-5000085F-D33B-4003-B28B-60B49874AB82 Q34382777-BBC2602D-0EBD-4487-A1D1-BBE3C683FE73 Q34635176-1011F547-B264-4077-B153-9654DDF7ED6D Q34759474-97EF2988-C782-4927-87BF-182C1EBB777F Q34849516-23856B17-750A-4C58-BE03-B6564FCD7A06 Q35018356-1B70711C-E6BD-4663-B350-CFCCB864F486 Q35040867-8651E594-2689-415E-98F6-6CA59CF7ADF1 Q35056226-411274DD-BBA3-40A9-8D4A-345C8DAB5A31 Q35093616-943E2B7D-909B-4B90-8B6A-656C749021C5 Q35146833-0BB60435-4B44-4B57-8FC2-FC8E994EDE42 Q35184806-FADAD5BB-435B-42A3-ABD5-C58D544642E8 Q35184831-20806451-0742-4FB1-A337-5BDBCB51C419 Q35234347-F91CC0F5-D9EC-4CF6-9A00-B2C31FD2845E Q35549348-881ACF8B-396B-4031-927A-C759EE28523A Q35599819-46C6E297-6D52-46C8-B9D3-CE3D8FED3AE2 Q35604265-F4084840-530B-4156-A842-5C87F2EE62CA Q35750289-E63601C4-F91A-47B9-9B33-78A4B2DFA8E1 Q35770218-C65971C2-6702-4339-9FE9-1BBFA7BBDEA9 Q35812731-4B2F6677-921B-49B5-A464-7F47F2755DA3 Q35873775-9F30BA13-88B9-406F-8C1B-420157DC365C Q35910772-ADC77701-F6FC-4C38-A125-59FD50E51E24 Q35938926-56F346B2-854C-4446-BB41-76222D87CA58 Q36005345-C4ACDCF0-5FE1-4A93-96B8-BFBB1B944C05 Q36051383-3FAA9AD4-4F45-4EB3-A0AF-954E1B87303B Q36121394-71BC1029-6CC4-4584-838D-631C32D7416C Q36173084-6B05A127-961A-40A8-933F-5B0AE21D57D4 Q36200143-02FC4120-C97D-4A99-946C-BC8434206769 Q36205399-0EE099F7-B5D7-4B2A-884B-4D7D6E7360EB Q36243701-94C777A4-BD0A-4AF5-9F6C-360F2884D48B Q36255703-FA8469A9-B324-4E80-8DF5-D8012494FFF7

P2860

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.

http://www.wikidata.org/entity/Q34038480

description

2002 nî lūn-bûn

@nan

2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.

@ast

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.

@en

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.

@nl

type

label

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.

@ast

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.

@en

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.

@nl

prefLabel

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.

@ast

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.

@en

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.

@nl

P1433

Q34038480-3CBFD5C3-944F-4BF6-AC63-54ABF625B592

P1476

Q34038480-46BBECAC-C926-4FCA-977C-8768B91407B3

P2093

Q34038480-31C3698B-B430-4ADC-8BFE-C1D8C7FCC305

Q34038480-40E04C1E-8507-4AF3-91E9-0E74836C20FA

Q34038480-4CDA45EC-B77B-46CB-946C-F1E032BDE907

Q34038480-53A9B409-0AF5-4736-829C-828EA03F2B61

Q34038480-620AAF6D-6EB1-475A-9FF3-C0CF75D57953

Q34038480-7629EAF3-3579-4E8B-B143-66BAA58AE527

Q34038480-8555185F-3ED1-47B2-B04E-B70B381420E1

Q34038480-8996297F-0976-43E6-B565-D338CB546DD4

Q34038480-96D9F3DA-3634-45E5-8998-2B3829161220

Q34038480-9A6528B7-40E0-4FC6-8CE5-0AC3A82C8618

P2860

Q34038480-10EB5B68-6B05-4761-B7BD-9B8BCBA710AB

Q34038480-115B47F6-C06D-4418-AE58-52F5DA0F93ED

Q34038480-1F19EACD-5891-42F3-B061-88B0D2EF801C

Q34038480-26C9E89F-2EA5-400F-AB88-2AC256B0EEF5

Q34038480-354A919A-ECCE-486C-A5F8-BB96F75AE430

Q34038480-4F8E1236-6811-492A-882F-C7B95AA88564

Q34038480-89EEF305-7B94-4987-93A1-998348E5D172

Q34038480-95734A5E-1C60-40F8-A72F-4898393D57F7

Q34038480-A643B9B3-E335-4276-8DF8-3202292BE5E7

Q34038480-AB154A28-6347-42D0-8240-A4DC759E46BE

P304

Q34038480-19B6C689-B1AC-4F1E-ADC3-B17F254A4E5B

P31

Q34038480-9417D503-1392-4067-8BD2-1F77676AD331

P356

Q34038480-49F0BD13-006B-46B6-9372-2E2E70628FC1

P407

Q34038480-52A711A7-AC47-4F88-8F63-D3F49AE1A103

P433

Q34038480-31E58A59-52D6-4C84-965A-21EB3C2F52C4

P478

Q34038480-CFF6FA88-D5FC-4363-ADDA-1FF765077DBB

P577

Q34038480-C9C3A220-BB47-4E3B-A396-6F34A9919DBC

P5875

Q34038480-757475E7-A49B-4F1B-9AE6-AC8291A2E9DF

P698

Q34038480-B83E9566-C7CF-4F42-ADDB-2524C1E59BC7

P932

Q34038480-5C2A80B2-9298-49F7-9FEA-D5C4E050E0C2

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.

@en

P2093

Anna Serur

http://www.w3.org/2001/XMLSchema#string

Christina A Manley

http://www.w3.org/2001/XMLSchema#string

Darrell J Yamashiro

http://www.w3.org/2001/XMLSchema#string

Eugene S Kim

http://www.w3.org/2001/XMLSchema#string

George D Yancopoulos

http://www.w3.org/2001/XMLSchema#string

Jason S Frischer

http://www.w3.org/2001/XMLSchema#string

Jessica J Kandel

http://www.w3.org/2001/XMLSchema#string

Jianzhong Huang

http://www.w3.org/2001/XMLSchema#string

Jocelyn Holash

http://www.w3.org/2001/XMLSchema#string

John S Rudge

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Vascular endothelial growth factor is a secreted angiogenic mitogen

All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor.

New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.

Clinical applications of angiogenic growth factors and their inhibitors.

Molecular events implicated in brain tumor angiogenesis and invasion.

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors

2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain.

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.

P304

11399-11404

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.172398399

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P577

2002-08-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11210709

http://www.w3.org/2001/XMLSchema#string

P698

12177446

http://www.w3.org/2001/XMLSchema#string

P932

123268

http://www.w3.org/2001/XMLSchema#string